aromasil has been researched along with Invasiveness, Neoplasm in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beliera, A; Carabantes, F; Ciruelos, E; Fernández, Y; Fonseca, R; García-Sáenz, JA; Gavilá, J; Martínez de Dueñas, E; Martínez-Jáñez, N; Murillo, L; Vidal, M | 1 |
| Bastiaannet, E; Hasenburg, A; Hozumi, Y; Jones, SE; Liefers, GJ; Marijnen, CA; Markopoulos, C; Paridaens, R; Putter, H; Rea, D; Scholten, AN; Seynaeve, C; van de Velde, CJ; van Hezewijk, M | 1 |
| Olin, JL; St Pierre, M | 1 |
| Athanassiou, G; Giannopoulou, E; Kalofonos, HP; Kalofonou, M; Koutras, A; Kritikou, I; Metsiou, D; Papachristou, DJ; Siatis, KE | 1 |
| Eng-Wong, J; Galbo, CE; Gallagher, A; Gatti-Mays, ME; Heckman-Stoddard, BM; Isaacs, C; Kallakury, B; Korde, L; Makariou, E; Reynolds, J; Singer, A; Venzon, D; Warren, R | 1 |
| Auboeuf, D; Bénès, V; Dalenc, F; Gratadou, L; Lacroix-Triki, M; Maillot, G; Millevoi, S; Pierredon, S; Roché, H; Schmidt, S; Vagner, S | 1 |
| Alés-Martínez, JE; Cheung, AM; Chlebowski, RT; Fabian, CJ; Farmer, P; Garber, JE; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, KC; Martin, LW; Maunsell, E; McTiernan, A; Pujol, P; Richardson, H; Robbins, J; Sarto, GE; Tu, D; Wactawski-Wende, J; Winquist, E | 1 |
| Brueggemeier, RW; Layman, RM; Lehman, AM; Lustberg, MB; Mrozek, E; Povoski, SP; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shiels, DR; Sugimoto, Y; Zhao, W; Ziegler, RM | 1 |
| Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M | 1 |
| Cruz Jurado, J; Fernández Martínez, R; Galve Calvo, E; García Mata, J; García Palomo, A; Murillo Jaso, L; Peláez Fernández, I; Polo Marqués, E; Richart Aznar, P; Sampedro Gimeno, T | 1 |
| Peeters, PH; van Diest, PJ; Verkooijen, HM | 1 |
2 review(s) available for aromasil and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Aromatase inhibitors in breast cancer prevention.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Invasiveness; Nitriles; Postmenopause; Risk; Triazoles | 2014 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease Management; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2011 |
7 trial(s) available for aromasil and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Safety; Survival Rate | 2018 |
Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; International Cooperation; Mastectomy, Segmental; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Reference Values; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome | 2013 |
Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety.
Topics: Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Bone Density; Breast Density; Breast Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lipids; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Postmenopause; Prognosis; Quality of Life; Risk Factors | 2016 |
Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth.
Topics: Androstadienes; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Northern; Blotting, Western; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Proliferation; Estrogen Antagonists; Estrogens; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pilot Projects; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Treatment Outcome | 2009 |
Exemestane for breast-cancer prevention in postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Neoplasm Invasiveness; Postmenopause; Quality of Life; Risk Factors | 2011 |
Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Pyrazoles; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sulfonamides; Survival Rate; Treatment Outcome | 2011 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Leukopenia; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Neutropenia; Paclitaxel; Receptors, Estrogen; Treatment Outcome | 2012 |
2 other study(ies) available for aromasil and Invasiveness, Neoplasm
| Article | Year |
|---|---|
The inhibition of aromatase alters the mechanical and rheological properties of non-small-cell lung cancer cell lines affecting cell migration.
Topics: Actins; Androstadienes; Apoptosis; Aromatase; Aromatase Inhibitors; Biomechanical Phenomena; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Shape; Cytoskeleton; Elastic Modulus; Humans; Lung Neoplasms; Neoplasm Invasiveness; Rheology; Tubulin; Vimentin | 2015 |
[Chemoprevention of breast cancer: exemestane ready to be tested in study setting].
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Cost-Benefit Analysis; Female; Humans; Incidence; Neoplasm Invasiveness; Postmenopause; Risk Factors | 2012 |